Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

Global Alliance for Pharmacogenomics

Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics.

15 Apr 2008

Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

11 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Study looks at denosumab in preventing bone loss caused by aromatase inhibitors

Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy.

17 Dec 2007

Discovery of novel mechanism to predict survival in older women with early stage lung cancer

A novel mechanism to predict survival in older women with early stage lung cancer has been uncoverecd by researchers at UCLA's Jonsson Comprehensive Cancer Center, a discovery that may have significant implications for new treatment approaches.

2 Nov 2007

Breast cancer awareness calls for cardiovascular awareness

Women who overcome breast cancer have every reason to celebrate. But a heart filled with joy may also be a heart damaged by life-saving cancer therapies, a growing body of research shows.

12 Oct 2007

HER-2 status predicts success of chemotherapy in breast cancer treatment

Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.

10 Oct 2007

More research needed on sex differences in lung cancer

The Society for Women's Health Research gathered three lung cancer experts on Capitol Hill on September 17, 2007 to inform Congress on the need for increased funding to research lung cancer and its impact on women.

1 Oct 2007

Risedronate prevents bone loss after breast cancer treatment

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research.

18 Sep 2007

TFAP2C gene may be useful target for new breast cancer therapies

University of Iowa researchers have discovered a gene that plays a linchpin role in the ability of breast cancer cells to respond to estrogen.

17 Sep 2007

Some with breast cancer stop taking aromatase inhibitors because of joint and muscle pain

More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

10 Sep 2007

Latest drugs improve survival for metastatic breast cancer

Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.

23 Jul 2007

Group therapy does not prolong the lives of women with metastatic breast cancer

Earlier results from the same researcher had suggested a survival benefit of group therapy for women with metastatic breast cancer. However, the new study did find that women with estrogen receptor (ER) negative tumors did show survival benefit, and that group therapy improved quality of life (QOL).

23 Jul 2007

Women well-informed about breast cancer although lack knowledge about current treatments

According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.

16 Jun 2007

Depression is a risk factor for osteoporosis

Evidence is accumulating that depression is a risk factor for osteoporosis, reports the June 2007 issue of Harvard Women's Health Watch.

30 May 2007

Women with breast cancer do not get potentially life-saving information

New published data from a large pan-European survey indicate that the majority of postmenopausal women with early breast cancer taking post-surgical endocrine therapy are not involved in making key decisions about their treatment, nor are they given sufficient information to make informed treatment choices that could affect their long-term outcome.

28 May 2007